

COMPANY ANNOUNCEMENT

PROFESSOR MARK HOGARTH RESIGNS FROM PRIMA BIOMED BOARD

Melbourne, Australia. 30 June 2005. Prima Biomed Ltd (ASX: PRR) announces the resignation of Professor Mark Hogarth from the Company's Board of Directors.

Professor Hogarth, who is also Executive Director of the Austin Research Institute ("ARI"), has worked diligently in representing the collective interests of Prima and the ARI in the Company's research projects; all of which are based on technologies emanating from the ARI. Professor Hogarth will continue to have a close affinity with the Company's projects in his ongoing role as the Executive Director at the ARI. Furthermore in his role as Chief Scientific Officer he will have a particularly close involvement in Prima's anti inflammatory project which is based on technology he initially discovered and developed.

The Company's Executive Chairman, Mr Eugene Kopp, in response to this news has said: "Mark has made a valuable contribution to the Company and to the development of its important research projects."

"Prima has been fortunate to have had such access to Mark's considerable scientific and general expertise. Since taking up his appointment on the Board, Mark has become the Executive Director of the ARI and thus his other corporate and administrative responsibilities have grown significantly."

In announcing his resignation Professor Hogarth has expressed his ongoing support and best wishes for the Company and its continuing efforts in the development of the research projects.

The Board of the Company express their thanks to Professor Hogarth for his service over a number of years as a director of the Company and its subsidiaries and look forward to his continued support of its research projects in his capacity as an ARI scientist and leader.

Company Contacts:

Company Enquiries	Mr Eugene Kopp	03 9854 5700
Media Enquiries	Rebecca Wilson	0417 382 391

About Prima BioMed Ltd

Prima BioMed (ASX: PRR) is a biotechnology company based in Melbourne and is developing technologies in the fields of immunology and cancer immunotherapy originating from the Austin Research Institute in Melbourne, Australia.

For further information, visit www.primabiomed.com.au

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward - looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward - looking statements are expressly qualified in their entirety by this cautionary statement.